Fig. 6: Combined treatment with JAK1/2 and SMAD3 inhibitors decreases fibrosis induced by MPN mesenchymal stromal cells. | Experimental & Molecular Medicine

Fig. 6: Combined treatment with JAK1/2 and SMAD3 inhibitors decreases fibrosis induced by MPN mesenchymal stromal cells.

From: Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms

Fig. 6

Bone marrow mesenchymal stromal cells (BM-MSCs) isolated from healthy donors (HDs) or patients with polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) were treated with ruxolitinib (Ruxo) or the SIS3 or JSH23 inhibitor or a combination for 48 h. a Immunofluorescence assay for α-smooth muscle actin (αSMA, green). Nuclei were counterstained with 4ʹ,6 diamidino-2-phenylindole (DAPI, blue). Scale bar 100 µm. b Percentage of αSMA-positive cells. c Immunofluorescence assay for fibronectin 1 (FN1, green). Nuclei are counterstained with DAPI (blue). Scale bar 100 µm. d Percentage of area with FN1 fluorescence. n = 3; b and d mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page